Campuzano-Maya G

Idioma: Español
Referencias bibliográficas: 176
Paginas: 411-442
Archivo PDF: 932.16 Kb.

RESUMEN

la hiperferritinemia, definida por ferritina sérica mayor de 200 μg/L en mujeres y de 300 μg/L en hombres, representa un reto para el clínico. De acuerdo con la etiología, la hiperferritinemia se puede subdividir en tres grupos: el primero correspondiente a la causada por enfermedades frecuentemente asociadas, como el síndrome metabólico, la hepatopatía alcohólica, la hepatopatía no alcohólica y procesos inflamatorios incluidas infecciones, enfermedades inflamatorias crónicas, enfermedades autoinmunes y algunos procesos malignos; el segundo, correspondiente a la causada por enfermedades poco frecuentemente asociadas, como la hemocromatosis hereditaria, algunas enfermedades hematológicas con anemia y la terapia transfusional permanente; y un tercer grupo, correspondiente a la causada por enfermedades raramente asociadas, como el síndrome hereditario de hiperferritinemia y cataratas, la aceruloplasminemia, la atransferrinemia o hipotransferrinemia, la porfiria cutánea tarda, la hemocromatosis neonatal, la sobrecarga de hierro africana y la enfermedad de Gaucher. El aspecto clínico más importante es definir, mediante la clínica y estudios simples y especializados, la causa asociada a la hiperferritinemia e intervenirla como punto de partida para su manejo. Desde el punto de vista del paciente es importante realizar estudios de ferrocinética (ferritina sérica y saturación de transferrina) y medición de sobrecarga de hierro en órganos blanco, mediante resonancia magnética, la cual presenta alta sensibilidad y especificidad. Todo esto significa la aplicación de algoritmos de manejo y seguimiento del paciente con hiperferritinemia. El manejo del síndrome depende de la etiología con la cual está asociada y la ausencia o presencia de sobrecarga de hierro, siendo, exclusivamente en este último caso, la flebotomía la mejor opción.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ogilvie C, Fitzsimons K, Fitzsimons EJ. Serum ferritin values in primary care: are high values overlooked? J Clin Pathol 2010;63:1124-1126.

2. Ho CH. The differential diagnostic values of serum transferrin receptor, serum ferritin and related parameters in the patients with various causes of anemia. Haematologica 2001;86:206- 207.

3. Birgegard G, Hallgren R, Killander A, Stromberg A, Venge P, Wide L. Serum ferritin during infection. A longitudinal study. Scand J Haematol 1978;21:333-340.

4. Herbert V, Jayatilleke E, Shaw S, Rosman AS, Giardina P, Grady RW, et al. Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. Stem Cells 1997;15:291-296.

5. Seyhan S, Pamuk ON, Pamuk GE, Cakir N. The correlation between ferritin level and acute phase parameters in rheumatoid arthritis and systemic lupus erythematosus. Eur J Rheumatol 2014;1:92-95.

6. Thachil J. The beneficial effect of acute phase increase in serum ferritin. Eur J Intern Med 2016;35:e16-e17.

7. Srai SK, Sharp P. Proteins of iron homeostasis In: Iron physiology and pathophysiology in humans, edited by Anderson GJ, McLaren GD. Brisbane, Australia: Humana Press, 2012, p. 3-26.

8. Wick M, Pinggera W, Lehmann P. Iron metabolism, diagnosis and therapy of anemias. New York: Springer, 1996.

9. Loréal O, Bardou-Jacquet E, Jouanolle AM, Gandon Y, Deugnier Y, Brissot P, et al. Metabolisme du fer et outils diagnostiques pour le clinicien. Rev Med Interne 2012;33 Suppl 1:S3- 9.

10. Beaumont C, Karim Z. Actualite du metabolisme du fer. Rev Med Interne 2013;34:17-25.

11. Pre J. La ferritine. Ann Med Interne (Paris) 1989;140:288-298.

12. Dezier JF, Vernet M. Determination de la ferritine serique. Interet et limites. Presse Med 1992;21:1283-1286.

13. Custer EM, Finch CA, Sobel RE, Zettner A. Population norms for serum ferritin. J Lab Clin Med 1995;126:88-94.

14. Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications. J Hepatol 2011;54:173-181.

15. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-7810.

16. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001;98:8780-8785.

17. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011;117:4425-4433.

18. Statland BE. Clinical decision levels for laboratory tests. Orandel NJ: Medical Economics Books: 1987.

19. McLaren GD, Gordeuk VR. Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Hematology Am Soc Hematol Educ Program 2009;195-206.

20. Worwood M. Serum ferritin. CRC Crit Rev Clin Lab Sci 1979;10:171-204.

21. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645.

22. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.

23. Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997;349:95-97.

24. Organización Mundial de la Salud. Obesidad y diabetes, una plaga lenta pero devastadora: discurso inaugural de la Directora General en la 47ª reunión de la Academia Nacional de Medicina. Disponible en http://www.who.int/dg/ speeches/2016/obesity-diabetes-disaster/es/. Consultado en febrero 2017.

25. Altes A, Remacha AF, Sureda A, Martino R, Briones J, Brunet S, et al. Patients with biochemical iron overload: causes and characteristics of a cohort of 150 cases. Ann Hematol 2003;82:127-130.

26. Freixenet N, Moreno-Rosel MS, Barcelo MJ, Serrano A, Paya M, Crespo L, et al. Detection of hereditary hemochromatosis and biochemical iron overload in primary care: a multicenter case finding study in Spain. Am J Hematol 2010;85:294-296.

27. Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De Matteis G, et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005;28:2061-2063.

28. Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004;363:357-362.

29. Deugnier Y, Bonnot P, Lainé F. Hépatosidérose dysmétabolique. Hepatogastroenterology 2008;15:19-24.

30. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander- Tetri BA, Chalasani N, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012;55:77-85.

31. Guillygomarc’h A, Mendler MH, Moirand R, Laine F, Quentin V, David V, et al. Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol 2001;35:344-349.

32. Lorcerie B, Audia S, Samson M, Milliere A, Falvo N, Leguy-Seguin V, et al. Démarche diagnostique devant une hyperferritinémie. Rev Med Interne 2015;36:522-529.

33. Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liver Dis 2005;9:37-53.

34. Yip WW, Burt AD. Alcoholic liver disease. Semin Diagn Pathol 2006;23:149-160.

35. Mathurin P, Beuzin F, Louvet A, Carrie-Ganne N, Balian A, Trinchet JC, et al. Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features. Aliment Pharmacol Ther 2007;25:1047-1054.

36. Carithers RL, McClain CJ. Alcoholic liver disease. In: Sleisenger and Fordtran´s Gastrointestinal and liver disease pathophysiology diagnosis management, edited by Feldman M, Friedman LS, Brandt LJ. Philadelphia: Saunders Elsevier, 2016, p. 1409-1427.

37. Moirand R, Lescoat G, Delamaire D, Lauvin L, Campion JP, Deugnier Y, et al. Increase in glycosylated and nonglycosylated serum ferritin in chronic alcoholism and their evolution during alcohol withdrawal. Alcohol Clin Exp Res 1991;15:963-969.

38. Harrison-Findik DD. Role of alcohol in the regulation of iron metabolism. World J Gastroenterol 2007;13:4925-4930.

39. Kohgo Y, Ohtake T, Ikuta K, Suzuki Y, Torimoto Y, Kato J. Dysregulation of systemic iron metabolism in alcoholic liver diseases. J Gastroenterol Hepatol 2008;23 Suppl 1:S78-81.

40. Sanvisens A, Rivas I, Bolao F, Tor J, Roson B, Rey-Joly C, et al. Genero y alteraciones hepaticas, nutricionales y metabolicas del alcoholismo grave: estudio de 480 pacientes. Med Clin (Barc) 2011;137:49-54.

41. Bell H, Skinningsrud A, Raknerud N, Try K. Serum ferritin and transferrin saturation in patients with chronic alcoholic and non-alcoholic liver diseases. J Intern Med 1994;236:315-322.

42. Adams PC, Barton JC. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. J Hepatol 2011;55:453-458.

43. Brissot P, Le Lan C, Troadec MB, Guillygomarc’h A, Lorho R, Jouanolle AM, et al. Que faire devant une hyperferritinémie ? Consultado junio 2017. Disponible http://www.fmcgastro.org/ wp-content/uploads/file/pdf/387.pdf. Paris: POST’U 2006.

44. Niemela O. Biomarkers in alcoholism. Clin Chim Acta 2007;377:39-49.

45. Hietala J, Koivisto H, Anttila P, Niemela O. Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers. Alcohol Alcohol 2006;41:528-533.

46. Mendenhall CL. Alcoholic hepatitis. Clin Gastroenterol 1981;10:417-441.

47. Helman RA, Temko MH, Nye SW, Fallon HJ. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med 1971;74:311-321.

48. Campuzano-Maya G. Del hemograma manual al hemograma de cuarta generación. Medicina & Laboratorio 2007;13:551-550.

49. Campuzano-Maya G. Electroforesis de proteínas. Medicina & Laboratorio 2006;7:679-694.

50. Michaut A, Moreau C, Robin MA, Fromenty B. Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. Liver Int 2014;34:e171-179.

51. Eastham EJ, Bell JI, Douglas AP. Serum ferritin levels in acute hepatocellular damage from paracetamol overdosage. Br Med J 1976;1:750- 751.

52. Wu J, Chen L, Chen Y, Yang J, Wu D. Serum ferritin concentration predicts mortality in patients with hepatitis B virus-related acute on chronic liver failure. Arch Med Res 2014;45:251-256.

53. Ferrara F, Ventura P, Vegetti A, Guido M, Abbati G, Corradini E, et al. Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. Am J Gastroenterol 2009;104:605-616.

54. Uchino K, Tateishi R, Fujiwara N, Minami T, Sato M, Enooku K, et al. Impact of serum ferritin level on hepatocarcinogenesis in chronic hepatitis C patients. Hepatol Res 2016;46:259- 268.

55. Le Page L, Leflon P, Mahevas M, Duhaut P, Smail A, Salle V, et al. Spectre etiologique des hyperferritinemies. Rev Med Interne 2005;26:368- 373.

56. Soundravally R, Agieshkumar B, Daisy M, Sherin J, Cleetus CC. Ferritin levels predict severe dengue. Infection 2015;43:13-19.

57. Jasmine YS, Lee SL, Kan FK. Infection associated haemophagocytic syndrome in severe dengue infection - a case series in a district hospital. Med J Malaysia 2017;72:62-64.

58. Anfasa F, Provacia L, GeurtsvanKessel C, Wever R, Gerstenbluth I, Osterhaus AD, et al. Hyperferritinemia is a potential marker of chronic chikungunya: A retrospective study on the Island of Curacao during the 2014-2015 outbreak. J Clin Virol 2017;86:31-38.

59. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-291.

60. Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev 2007;6:457-463.

61. Williams MR, Turkes A, Pearson D, Griffiths K, Blamey RW. Serum ferritin as a marker of therapeutic response in stage III and IV breast cancer. Eur J Surg Oncol 1990;16:22-27.

62. Shpyleva SI, Tryndyak VP, Kovalchuk O, Starlard- Davenport A, Chekhun VF, Beland FA, et al. Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat 2011;126:63-71.

63. Orlandi R, De Bortoli M, Ciniselli CM, Vaghi E, Caccia D, Garrisi V, et al. Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Ann Oncol 2014;25:352-357.

64. Kukulj S, Jaganjac M, Boranic M, Krizanac S, Santic Z, Poljak-Blazi M. Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer. Med Oncol 2010;27:268-277.

65. Shi HB, Li XD, Jiang JT, Zhao WQ, Ji M, Wu CP. Serum ferritin is elevated in advanced nonsmall cell lung cancer patients and is associated with efficacy of platinum-based chemotherapy. J Cancer Res Ther 2014;10:681-685.

66. Yuan CC, Ng HT, Yeh SH, Chen SS, Hsu DS, Ho CH. Hyperferritinemia in ovarian cancer. J Reprod Med 1988;33:193-195.

67. Akiba S, Neriishi K, Blot WJ, Kabuto M, Stevens RG, Kato H, et al. Serum ferritin and stomach cancer risk among a Japanese population. Cancer 1991;67:1707-1712.

68. Nomura A, Chyou PH, Stemmermann GN. Association of serum ferritin levels with the risk of stomach cancer. Cancer Epidemiol Biomarkers Prev 1992;1:547-550.

69. Hann HW, Stahlhut MW, Evans AE. Basic and acidic isoferritins in the sera of patients with neuroblastoma. Cancer 1988;62:1179-1182.

70. Potaznik D, Groshen S, Miller D, Bagin R, Bhalla R, Schwartz M, et al. Association of serum iron, serum transferrin saturation, and serum ferritin with survival in acute lymphocytic leukemia. Am J Pediatr Hematol Oncol 1987;9:350- 355.

71. Chang LS, Yu HR, Chen YC, Yeah ST, Tiao MM, Hsiao CC, et al. Acute lymphoblastic leukemia presented as severe jaundice and hyperferritinemia: a case report. J Pediatr Hematol Oncol 2011;33:e117-119.

72. Artz AS, Logan B, Zhu X, Akpek G, Bufarull RM, Gupta V, et al. The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica 2016;101:1426-1433.

73. Brierley CK, Revuelta Iniesta R, Storrar N, Thomas AE. Hyperferritinemia in Pediatric Acute Lymphoblastic Leukemia: What Does it Mean? J Pediatr Hematol Oncol 2017;39:238.

74. Yamazaki E, Tomita N, Koyama S, Ogusa E, Ishii Y, Takahashi H, et al. Serum ferritin level is prognostic of patient outcome in extranodal NK/T cell lymphoma, nasal type. Med Oncol 2014;31:149.

75. Yoh KA, Lee HS, Park LC, Lee EM, Shin SH, Park DJ, et al. The prognostic significance of elevated levels of serum ferritin before chemotherapy in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2014;14:43-49.

76. Koyama S, Fujisawa S, Watanabe R, Itabashi M, Ishibashi D, Ishii Y, et al. Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma. Int J Lab Hematol 2017;39:112-117.

77. Fernandez-Alvarez R, Gonzalez-Rodriguez AP, Gonzalez ME, Rubio-Castro A, Dominguez-Iglesias F, Solano J, et al. Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy. Leuk Lymphoma 2015;1-19.

78. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-131.

79. Lin TF, Ferlic-Stark LL, Allen CE, Kozinetz CA, McClain KL. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer 2011;56:154-155.

80. Jacobs A. Serum ferritin and malignant tumours. Med Oncol Tumor Pharmacother 1984;1:149-156.

81. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: Past, present and future. Biochim Biophys Acta 2010;1800:760-769.

82. Gasser B, Courtois F, Hojjat-Assari S, Sauleau EA, Buffet C, Brissot P. Hemochromatose hereditaire: circonstances de decouverte et delais diagnostiques. Rev Med Interne 2014;35:160- 165.

83. Wong K, Adams PC. The diversity of liver diseases among outpatient referrals for an elevated serum ferritin. Can J Gastroenterol 2006;20:467-470.

84. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-724.

85. Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM. Ferritin for the clinician. Blood Rev 2009;23:95-104.

86. Anderson GJ. Mechanisms of iron loading and toxicity. Am J Hematol 2007;82:1128-1131.

87. Lobo C, Angulo IL, Aparicio LR, Drelichman GI, Zanichelli MA, Cancado R, et al. Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload--the RELATH study. Hematology 2011;16:265-273.

88. Girelli D, Olivieri O, De Franceschi L, Corrocher R, Bergamaschi G, Cazzola M. A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. Br J Haematol 1995;90:931- 934.

89. Bonneau D, Winter-Fuseau I, Loiseau MN, Amati P, Berthier M, Oriot D, et al. Bilateral cataract and high serum ferritin: a new dominant genetic disorder? J Med Genet 1995;32:778- 779.

90. Cazzola M, Bergamaschi G, Tonon L, Arbustini E, Grasso M, Vercesi E, et al. Hereditary hyperferritinemia- cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin lightchain mRNA. Blood 1997;90:814-821.

91. Luscieti S, Tolle G, Aranda J, Campos CB, Risse F, Moran E, et al. Novel mutations in the ferritin- L iron-responsive element that only mildly impair IRP binding cause hereditary hyperferritinaemia cataract syndrome. Orphanet J Rare Dis 2013;8:30.

92. Arnold JD, Mumford AD, Lindsay JO, Hegde U, Hagan M, Hawkins JR. Hyperferritinaemia in the absence of iron overload. Gut 1997;41:408- 410.

93. Ferrante M, Geubel AP, Fevery J, Marogy G, Horsmans Y, Nevens F. Hereditary hyperferritinaemia- cataract syndrome: a challenging diagnosis for the hepatogastroenterologist. Eur J Gastroenterol Hepatol 2005;17:1247-1253.

94. Yin D, Kulhalli V, Walker AP. Raised serum ferritin concentration in hereditary hyperferritinemia cataract syndrome is not a marker for iron overload. Hepatology 2014;59:1204-1206.

95. Miyajima H, Nishimura Y, Mizoguchi K, Sakamoto M, Shimizu T, Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987;37:761-767.

96. Kono S. Aceruloplasminemia: an update. Int Rev Neurobiol 2013;110:125-151.

97. Miyajima H. Aceruloplasminemia. Neuropathology 2015;35:83-90.

98. Heilmeyer L, Keller W, Vivell O, Keiderling W, Betke K, Woehler F, et al. [Congenital atransferrinemia in a 7-year-old girl]. Dtsch Med Wochenschr 1961;86:1745-1751.

99. Hamill RL, Woods JC, Cook BA. Congenital atransferrinemia. A case report and review of the literature. Am J Clin Pathol 1991;96:215- 218.

100. Shamsian BS, Rezaei N, Arzanian MT, Alavi S, Khojasteh O, Eghbali A. Severe hypochromic microcytic anemia in a patient with congenital atransferrinemia. Pediatr Hematol Oncol 2009;26:356-362.

101. Bulat V, Lugovic L, Situm M, Buljan M, Bradic L. Porphyria cutanea tarda as the most common porphyria. Acta Dermatovenerol Croat 2007;15:254-263.

102. Ryan Caballes F, Sendi H, Bonkovsky HL. Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int 2012;32:880-893.

103. Yang XM, Zhang Y, Wang T, Liu YH. Sporadic Porphyria Cutanea Tarda Induced by Alcohol Abuse. Chin Med J (Engl) 2017;130:2011-2012.

104. Rocchi E, Gibertini P, Cassanelli M, Pietrangelo A, Jensen J, Ventura E. Hepatitis B virus infection in porphyria cutanea tarda. Liver 1986;6:153-157.

105. Stransky J, Malina L, Cieslarova B, Stritesky J, Putova I, Horak J. Overt and hidden coinfection with hepatitis B and C viruses in chronic liver disease and porphyria cutanea tarda. Acta Virol 2000;44:23-28.

106. Callen JP. Hepatitis C Viral Infection and Porphyria Cutanea Tarda. Am J Med Sci 2017;354:5- 6.

107. Franzon VA, Mikilita ES, Camelo FH, Camargo R. Porphyria cutanea tarda in a HIV- positive patient. An Bras Dermatol 2016;91:520-523.

108. Hift RJ. Porphyria cutanea tarda, iron, inflammation and diabetes mellitus. Br J Dermatol 2011;165:453-454.

109. Haendchen L, Jordao JM, Haider O, Araujo F, Skare TL. Porphyria cutanea tarda and systemic lupus erythematosus. An Bras Dermatol 2011;86:173-175.

110. Fritsch S, Wojcik AS, Schade L, Machota Junior MM, Brenner FM, Paiva Edos S. Increased photosensitivity? Case report of porphyria cutanea tarda associated with systemic lupus erythematosus. Rev Bras Reumatol 2012;52:968-970.

111. Fang S, Sun X, Wang Z, Song D, Li T. Porphyria cutanea tarda and Sjogren’s syndrome. An Bras Dermatol 2014;89:689-691.

112. Syn WK, Ahmed MM. Genetic haemochromatosis presenting as porphyria cutanea tarda. Int J Clin Pract Suppl 2005;48-50.

113. de Geus HR, Dees A. Sporadic porphyria cutanea tarda due to haemochromatosis. Neth J Med 2006;64:307-309.

114. Toll A, Celis R, Ozalla MD, Ercilla MG, Herrero C. Haemochromatosis gene mutations and response to chloroquine in sporadic porphyria cutanea tarda. Acta Derm Venereol 2006;86:279- 280.

115. Young LC. Porphyria cutanea tarda associated with Cys282Tyr mutation in HFE gene in hereditary hemochromatosis: a case report and review of the literature. Cutis 2007;80:415-418.

116. Trofymenko O, Sagerman P, Kurtzman DJB. Porphyria Cutanea Tarda as the Initial Manifestation of Subclinical Hereditary Hemochromatosis. Clin Gastroenterol Hepatol 2017;15:A37- A38.

117. Cruz MJ, Alves S, Baudrier T, Azevedo F. Porphyria cutanea tarda induced by tamoxifen. Dermatol Online J 2010;16:2.

118. Mas-Vidal A, Coto-Segura P, Garcia-Varona A, Santos-Juanes J. Porphyria cutanea tarda induced by olmesartan. J Eur Acad Dermatol Venereol 2010;24:977-978.

119. Lambrecht RW, Thapar M, Bonkovsky HL. Genetic aspects of porphyria cutanea tarda. Semin Liver Dis 2007;27:99-108.

120. Cottier H. Ueber ein der hamochromatose vergleichbares krankheitsbild bei neugeborenen. Schweiz Med Wochenschr 1957;37:39-43.

121. Zoller H, Knisely AS. Control of iron metabolism-- lessons from neonatal hemochromatosis. J Hepatol 2012;56:1226-1229.

122. Bonilla S, Prozialeck JD, Malladi P, Pan X, Yu S, Melin-Aldana H, et al. Neonatal iron overload and tissue siderosis due to gestational alloimmune liver disease. J Hepatol 2012;56:1351- 1355.

123. Lopriore E, Mearin ML, Oepkes D, Devlieger R, Whitington PF. Neonatal hemochromatosis: management, outcome, and prevention. Prenat Diagn 2013;33:1221-1225.

124. Sundaram SS, Alonso EM, Narkewicz MR, Zhang S, Squires RH, Pediatric Acute Liver Failure Study G. Characterization and outcomes of young infants with acute liver failure. J Pediatr 2011;159:813-818 e811.

125. Heissat S, Collardeau-Frachon S, Baruteau J, Dubruc E, Bouvier R, Fabre M, et al. Neonatal hemochromatosis: diagnostic work-up based on a series of 56 cases of fetal death and neonatal liver failure. J Pediatr 2015;166:66-73.

126. Korkmaz L, Bastug O, Daar G, Doganay S, Deniz K, Kurtoglu S. Neonatal hemochromatosis in monochorionic twins. J Neonatal Perinatal Med 2015;8:413-416.

127. Grabhorn E, Richter A, Burdelski M, Rogiers X, Ganschow R. Neonatal hemochromatosis: long-term experience with favorable outcome. Pediatrics 2006;118:2060-2065.

128. Relvas L, Claro MT, Bento MC, Ribeiro ML. Novel human pathological mutations. Gene symbol: SLC40A1. Disease: haemochromatosis, type 4. Hum Genet 2009;125:338.

129. Takamatsu J, Majima M, Miki K, Kuma K, Mozai T. Serum ferritin as a marker of thyroid hormone action on peripheral tissues. J Clin Endocrinol Metab 1985;61:672-676.

130. Stein P, Yu H, Jain D, Mistry PK. Hyperferritinemia and iron overload in type 1 Gaucher disease. Am J Hematol 2010;85:472-476.

131. Said R. L’hyperthyroidie: une cause d’elevation de la ferritine serique. Rev Med Interne 2000;21:1129-1131.

132. Franchini M. Hereditary iron overload: update on pathophysiology, diagnosis, and treatment. Am J Hematol 2006;81:202-209.

133. Michot JM, Hie M, Galicier L, Lambotte O, Michel M, Bloch-Queyrat C, et al. Le syndrome d’activation lymphohistiocytaire de l’adulte. Rev Med Interne 2013;34:85-93.

134. Dhote R, Simon J, Papo T, Detournay B, Sailler L, Andre MH, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum 2003;49:633-639.

135. Pouchot J, Vinceneux P. Diagnostic, evolution et pronostic, pathogenie et traitement de la maladie de Still de l’adulte. Presse Med 2004;33:1019-1026.

136. Vignes S, Le Moel G, Fautrel B, Wechsler B, Godeau P, Piette JC. Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still’s disease. Ann Rheum Dis 2000;59:347-350.

137. Rosario C, Zandman-Goddard G, Meyron-Holtz EG, D’Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med 2013;11:185.

138. Agmon-Levin N, Rosario C, Katz BS, Zandman- Goddard G, Meroni P, Cervera R, et al. Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). Lupus 2013;22:1327- 1335.

139. Garcia PC, Longhi F, Branco RG, Piva JP, Lacks D, Tasker RC. Ferritin levels in children with severe sepsis and septic shock. Acta Paediatr 2007;96:1829-1831.

140. Siegelman ES, Mitchell DG, Semelka RC. Abdominal iron deposition: metabolism, MR findings, and clinical importance. Radiology 1996;199:13-22.

141. Queiroz-Andrade M, Blasbalg R, Ortega CD, Rodstein MA, Baroni RH, Rocha MS, et al. MR imaging findings of iron overload. Radiographics 2009;29:1575-1589.

142. Tavill AS, Adams PC. A diagnostic approach to hemochromatosis. Can J Gastroenterol 2006;20:535-540.

143. Bassett ML, Hickman PE, Dahlstrom JE. The changing role of liver biopsy in diagnosis and management of haemochromatosis. Pathology 2011;43:433-439.

144. Angelucci E, Baronciani D, Lucarelli G, Baldassarri M, Galimberti M, Giardini C, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol 1995;89:757-761.

145. Koh TS, Benson TH, Judson GJ. Trace element analysis of bovine liver: interlaboratory survey in Australia and New Zealand. J Assoc Off Anal Chem 1980;63:809-813.

146. Villeneuve JP, Bilodeau M, Lepage R, Cote J, Lefebvre M. Variability in hepatic iron concentration measurement from needle-biopsy specimens. J Hepatol 1996;25:172-177.

147. Emond MJ, Bronner MP, Carlson TH, Lin M, Labbe RF, Kowdley KV. Quantitative study of the variability of hepatic iron concentrations. Clin Chem 1999;45:340-346.

148. Wood JC. Guidelines for quantifying iron overload. Hematology Am Soc Hematol Educ Program 2014;2014:210-215.

149. Pipaliya N, Solanke D, Parikh P, Ingle M, Sharma R, Sharma S, et al. Comparison of tissue elastography with magnetic resonance imaging T2* and serum ferritin quantification in detecting liver iron overload in patients with thalassemia major. Clin Gastroenterol Hepatol 2017;15:292-298 e291.

150. Kim JR, Suh CH, Yoon HM, Lee JS, Cho YA, Jung AY. The diagnostic performance of shear-wave elastography for liver fibrosis in children and adolescents: A systematic review and diagnostic meta-analysis. Eur Radiol 2018;28:1175- 1186.

151. Ilan Y. Review article: the assessment of liver function using breath tests. Aliment Pharmacol Ther 2007;26:1293-1302.

152. Campuzano-Maya G. Pruebas de aliento basadas en sustratos marcados con carbono 13. Medicina & Laboratorio 2011;17:39-79.

153. Brittenham GM, Badman DG, National Institute of D, Digestive, Kidney Diseases W. Noninva sive measurement of iron: report of an NIDDK workshop. Blood 2003;101:15-19.

154. Pietrangelo A. Hereditary hemochromatosis- -a new look at an old disease. N Engl J Med 2004;350:2383-2397.

155. Jensen PD. Evaluation of iron overload. Br J Haematol 2004;124:697-711.

156. Bonkovsky HL, Rubin RB, Cable EE, Davidoff A, Rijcken TH, Stark DD. Hepatic iron concentration: noninvasive estimation by means of MR imaging techniques. Radiology 1999;212:227- 234.

157. Rose C, Vandevenne P, Bourgeois E, Cambier N, Ernst O. Liver iron content assessment by routine and simple magnetic resonance imaging procedure in highly transfused patients. Eur J Haematol 2006;77:145-149.

158. Gandon Y. Iron, liver and MRI. Disponible en: http://www.radio.univ-rennes1.fr /Sources/EN/ Hemo.html. Consultado octubre 2017.

159. Powell LW, Dixon JL, Ramm GA, Purdie DM, Lincoln DJ, Anderson GJ, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006;166:294-301.

160. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000;33:485-504.

161. Papakonstantinou O, Kostaridou S, Maris T, Gouliamos A, Premetis E, Kouloulias V, et al. Quantification of liver iron overload by T2 quantitative magnetic resonance imaging in thalassemia: impact of chronic hepatitis C on measurements. J Pediatr Hematol Oncol 1999;21:142-148.

162. Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med 1993;328:1616- 1620.

163. Wood JC. Use of magnetic resonance imaging to monitor iron overload. Hematol Oncol Clin North Am 2014;28:747-764, vii.

164. Wells SA. Quantification of hepatic fat and iron with magnetic resonance imaging. Magn Reson Imaging Clin N Am 2014;22:397-416.

165. Sarigianni M, Liakos A, Vlachaki E, Paschos P, Athanasiadou E, Montori VM, et al. Accuracy of magnetic resonance imaging in diagnosis of liver iron overload: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015;13:55-63 e55.

166. Brissot P, Bardou-Jacquet E, Jouanolle AM, Loreal O. Iron disorders of genetic origin: a changing world. Trends Mol Med 2011;17:707-713.

167. Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000;25:14-15.

168. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003;33:21-22.

169. Papanikolaou G, Samuels ME, Ludwig EH, Mac- Donald ML, Franchini PL, Dube MP, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004;36:77-82.

170. Kannengiesser C, Jouanolle AM, Hetet G, Mosser A, Muzeau F, Henry D, et al. A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload. Haematologica 2009;94:335-339.

171. Thurlow V, Vadher B, Bomford A, DeLord C, Kannengiesser C, Beaumont C, et al. Two novel mutations in the L ferritin coding sequence associated with benign hyperferritinaemia unmasked by glycosylated ferritin assay. Ann Clin Biochem 2012;49:302-305.

172. European Association For The Study Of The L. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010;53:3-22.

173. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007;102:1251-1258.

174. Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000;31:730-736.

175. Desai TK, Jamil LH, Balasubramaniam M, Koff R, Bonkovsky HL. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci 2008;53:815-822.

176. Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Blood 2012;120:4496-4504.